Exclusive Sales Agreement Signed with Middle Eastern Partner Health Arena for Portable Electrocardiograph 'HATIV P30'

VUNO, a medical artificial intelligence (AI) company, has secured its first export results in the Middle East, marking a step forward in expanding into overseas markets.


On July 1, VUNO announced that it recently signed an exclusive sales agreement with healthcare specialist company Health Arena for its AI-powered portable electrocardiograph 'HATIV P30' in five countries: Egypt, United Arab Emirates, Saudi Arabia, Kuwait, and Iraq.


Vuno and Health Arena are jointly operating an exhibition booth at 'CardioAlex.' Vuno

Vuno and Health Arena are jointly operating an exhibition booth at 'CardioAlex.' Vuno

View original image

This agreement represents VUNO's first export achievement in the Middle East. Last month, the two companies jointly operated an exhibition booth at 'CardioAlex,' the largest cardiology conference in the Middle East and Africa, held in Egypt, where they showcased the HATIV P30.


HATIV P30 is a portable electrocardiogram (ECG) device based on six-lead measurement. According to the company, its user-friendly testing method and global regulatory approvals have drawn attention from local medical professionals and stakeholders.


The digital healthcare solutions market in the Middle East is growing due to the expansion of telemedicine adoption and increasing demand for improved medical accessibility. VUNO plans to use this agreement as an opportunity to expand local partnerships and increase the supply of its medical AI solutions in the region.


Previously, VUNO also participated in the '38th Asia-Pacific Association of Cataract and Refractive Surgeons (APACRS)' held in Thailand, where it showcased its AI-based fundus imaging diagnostic support device, 'VUNO Med-Fundus AI.'


VUNO operated a joint booth with its Thai partner, strengthening its ties with local medical professionals. Fundus AI analyzes fundus images to present abnormal findings necessary for disease diagnosis. VUNO is exploring the device's potential in Southeast Asian markets, where there is a shortage of ophthalmology specialists.


Yehha Lee, CEO of VUNO, said, "Through international medical events, we have confirmed strong local interest in our solutions," adding, "We will accelerate our entry into the global market based on our proven product competitiveness and local partnerships."



VUNO is focusing on expanding overseas markets centered on its AI-based cardiac arrest prediction device, 'VUNO Med-DeepCARS.' The company is collaborating with European medical institutions and medical information system companies to build a foundation for adoption by overseas healthcare providers.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing